Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Asset Utilization Ratio: 2015-2025

Historic Asset Utilization Ratio for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to 0.18.

  • ImmunityBio's Asset Utilization Ratio rose 888.83% to 0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18, marking a year-over-year increase of 888.83%. This contributed to the annual value of 0.03 for FY2024, which is 2215.61% up from last year.
  • As of Q3 2025, ImmunityBio's Asset Utilization Ratio stood at 0.18, which was up 11.77% from 0.16 recorded in Q2 2025.
  • ImmunityBio's Asset Utilization Ratio's 5-year high stood at 0.18 during Q3 2025, with a 5-year trough of 0.00 in Q1 2024.
  • Over the past 3 years, ImmunityBio's median Asset Utilization Ratio value was 0.00 (recorded in 2024), while the average stood at 0.05.
  • In the last 5 years, ImmunityBio's Asset Utilization Ratio tumbled by 75.45% in 2022 and then spiked by 13,527.09% in 2025.
  • ImmunityBio's Asset Utilization Ratio (Quarterly) stood at 0.00 in 2021, then tumbled by 75.45% to 0.00 in 2022, then surged by 97.87% to 0.00 in 2023, then soared by 2,871.13% to 0.04 in 2024, then spiked by 888.83% to 0.18 in 2025.
  • Its last three reported values are 0.18 in Q3 2025, 0.16 for Q2 2025, and 0.09 during Q1 2025.